Jefferies Financial Group Inc. Acquires 81,697 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Jefferies Financial Group Inc. increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 201.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,322 shares of the company’s stock after purchasing an additional 81,697 shares during the period. Jefferies Financial Group Inc.’s holdings in Structure Therapeutics were worth $3,825,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Parallel Advisors LLC increased its holdings in shares of Structure Therapeutics by 12.7% during the 3rd quarter. Parallel Advisors LLC now owns 8,286 shares of the company’s stock valued at $259,000 after acquiring an additional 934 shares during the last quarter. Alps Advisors Inc. raised its stake in Structure Therapeutics by 31.6% during the 3rd quarter. Alps Advisors Inc. now owns 94,499 shares of the company’s stock valued at $2,955,000 after purchasing an additional 22,666 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Structure Therapeutics in the third quarter valued at about $132,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Structure Therapeutics by 20.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,957 shares of the company’s stock worth $489,000 after acquiring an additional 2,548 shares during the period. Finally, Sterling Capital Management LLC lifted its position in Structure Therapeutics by 63.6% in the third quarter. Sterling Capital Management LLC now owns 3,345 shares of the company’s stock worth $105,000 after purchasing an additional 1,300 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $19.84 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $18.70 and a 1 year high of $94.90. The stock’s 50-day moving average price is $28.43 and its two-hundred day moving average price is $46.40.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). On average, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -2.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on GPCR shares. Weiss Ratings upgraded shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen lowered shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a research note on Thursday. Finally, Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.